( NASDAQ: WKHS) has dropped by around $2 a share in the past seven and a half days. The gain had been pared to about 1.2% by noon. The stock traded up as much as 10% in Tuesday’s after-hours session and was about 8% in Wednesday’s premarket. Army contract valued at more than $800 million. A short seller report released Tuesday absolutely blistered the company, and the CEO’s response did little to stop the bloodletting.Īs we noted in our morning report on meme stocks, Palantir Technologies Inc. ( NYSEAMERICAN: CEI) dropped more than 50% on Tuesday and traded down by about 20% at the noon hour Wednesday. The lackluster growth estimates also are likely to raise talk of future stagflation.Īmong meme stocks, losers outnumbered gainers, and Wednesday’s biggest loser was also Tuesday’s big loser. economy has reached its peak growth (6.3% and 6.7% real GDP growth in the first and second quarters, respectively). The Atlanta Federal Reserve’s GDPNow forecast for third-quarter GDP growth came in at a disappointing 1.3%. All three major indexes traded in the red, with the Nasdaq Composite showing the smallest loss and the Dow Jones industrials, the largest. should help secure Bitcoin block rewards.At noon on Wednesday, the markets were trying to dig their way out of a hole that deepened earlier in the morning. In a game where numbers do matter, having one of the largest crypto mining fleets in the U.S. The expectation is Marathon Digital will have over 133,000 active miners in its fleet by the midpoint of next year. There are more than 100,000 miners purchased and waiting for delivery. A Bitcoin block reward totals 6.25 tokens, worth about $300,000.Īs of the beginning of October, the company had 25,272 active mining devices in its fleet. In Marathon Digital's case, it's specifically mining for Bitcoin ( BTC -1.56%), the largest digital currency by market cap. The reward for validating a block is almost always paid in the tokens of the underlying blockchain being validated. Groups of these transactions are known as blocks. The expectation is for Marathon Digital to grow its sales from a reported $4.36 million in 2020 to a consensus of $838 million by 2023.įor those unfamiliar, cryptocurrency mining describes the process whereby people or a company use high-powered computers to solve complex mathematical equations that validate transactions on a blockchain. If 1,334% sales growth in three years simply isn't good enough, perhaps the more than 19,000% sales growth expected from cryptocurrency mining company Marathon Digital Holdings ( MARA -2.46%) will wet your whistle. Marathon Digital Holdings: 19,120% implied sales growth by 2023 With research into COVID-19 variants ongoing and constantly evolving, Wall Street's sales estimates can probably be taken with a grain of salt. What's more, it's unclear what sort of demand will be present with regard to booster shots. The expectation is that we could see new players enter the vaccine space in the months and years that lie ahead. However, what's interesting about Moderna's sales projections in 2023 is that they're markedly lower than the $20 billion-plus in net product sales forecast by the company this year. Only the Pfizer/ BioNTech vaccine, with its 95% initial VE, has been able to go toe-to-toe with Moderna's vaccine. This initial VE has stood head-and-shoulders above a number of competitors, including Johnson & Johnson and AstraZeneca, which have both been contending with concerns over rare incidences of blood clotting associated with their respective COVID-19 vaccines. The company's vaccine, mRNA-1273, produced an impressive 94% vaccine efficacy (VE) in a November-released study. Moderna is one of the two standout COVID-19 vaccine developers in the United States and Europe. After reporting a little over $803 million in sales last year, Wall Street's consensus calls for $11.52 billion in full-year sales by 2023.
The most well-known hypergrowth company, at least on this list, is biotech stock Moderna ( MRNA -1.81%), which is benefiting immensely from selling its coronavirus disease 2019 (COVID-19) vaccine. Moderna: 1,334% implied sales growth by 2023
0 kommentar(er)
